Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | SARS-CoV-2 | Research

Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study

Authors: Guillaume Martin-Blondel, François-Xavier Lescure, Lambert Assoumou, Charlotte Charpentier, Jean-Marc Chapplain, Thomas Perpoint, Gaspard Grouteau, Hugues Cordel, Gilles Pialoux, Jérome Pacanowski, Michael Thy, Adeline Bauvois, Didier Laureillard, Fadia Hamrouni, Michèle Algarte-Genin, Julien Poissy, Diane Descamps, Dominique Costagliola, for the CoCliCo Study Group

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

The impact of the variant of concern (VOC) Alpha on the severity of COVID-19 has been debated. We report our analysis in France.

Methods

We conducted an exposed/unexposed cohort study with retrospective data collection, comparing patients infected by VOC Alpha to contemporaneous patients infected by historical lineages. Participants were matched on age (± 2.5 years), sex and region of hospitalization. The primary endpoint was the proportion of hospitalized participants with severe COVID-19, defined as a WHO-scale > 5 or by the need of a non-rebreather mask, occurring up to day 29 after admission. We used a logistic regression model stratified on each matched pair and accounting for factors known to be associated with the severity of the disease.

Results

We included 650 pairs of patients hospitalized between Jan 1, 2021, and Feb 28, 2021, in 47 hospitals. Median age was 70 years and 61.3% of participants were male. The proportion of participants with comorbidities was high in both groups (85.0% vs 90%, p = 0.004). Infection by VOC Alpha was associated with a higher odds of severe COVID-19 (41.7% vs 38.5%—aOR = 1.33 95% CI [1.03–1.72]).

Conclusion

Infection by the VOC Alpha was associated with a higher odds of severe COVID-19.
Appendix
Available only for authorised users
Literature
3.
go back to reference Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:6538.CrossRef Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:6538.CrossRef
6.
8.
go back to reference Nyberg T, Twohig KA, Harris RJ, Seaman SR, Flannagan J, Allen H, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ. 2021;373:n1412.CrossRef Nyberg T, Twohig KA, Harris RJ, Seaman SR, Flannagan J, Allen H, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ. 2021;373:n1412.CrossRef
9.
go back to reference Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372: n579.CrossRef Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372: n579.CrossRef
13.
17.
go back to reference Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192-e7. Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192-e7.
18.
go back to reference Hung IF, Cheng VC, Wu AK, Tang BS, Chan KH, Chu CM, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004;10(9):1550–7.CrossRef Hung IF, Cheng VC, Wu AK, Tang BS, Chan KH, Chu CM, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004;10(9):1550–7.CrossRef
19.
go back to reference Calistri P, Amato L, Puglia I, Cito F, Di Giuseppe A, Danzetta ML, et al. Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs. Int J Infect Dis. 2021;105:753–5.CrossRef Calistri P, Amato L, Puglia I, Cito F, Di Giuseppe A, Danzetta ML, et al. Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs. Int J Infect Dis. 2021;105:753–5.CrossRef
20.
go back to reference Teyssou E, Soulie C, Visseaux B, Lambert-Niclot S, Ferre V, Marot S, et al. The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. J Infect. 2021;83(1):119–45. https://doi.org/10.1016/j.jinf.2021.04.023. Teyssou E, Soulie C, Visseaux B, Lambert-Niclot S, Ferre V, Marot S, et al. The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. J Infect. 2021;83(1):119–45. https://​doi.​org/​10.​1016/​j.​jinf.​2021.​04.​023.
Metadata
Title
Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study
Authors
Guillaume Martin-Blondel
François-Xavier Lescure
Lambert Assoumou
Charlotte Charpentier
Jean-Marc Chapplain
Thomas Perpoint
Gaspard Grouteau
Hugues Cordel
Gilles Pialoux
Jérome Pacanowski
Michael Thy
Adeline Bauvois
Didier Laureillard
Fadia Hamrouni
Michèle Algarte-Genin
Julien Poissy
Diane Descamps
Dominique Costagliola
for the CoCliCo Study Group
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07508-x

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue